General MedicationsORALGeneric
BILOPAQUE
TYROPANOATE SODIUM
Standard Dose
750MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview BILOPAQUE is listed in Drugs@FDA under application 013731 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient TYROPANOATE SODIUM Form and strength CAPSULE;ORAL - 750MG Sponsor GE HEALTHCARE Submission history Latest submission status date: 1995-02-22 00:00:00.
Structured Monograph
Clinical summary
Approval overview BILOPAQUE is listed in Drugs@FDA under application 013731 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TYROPANOATE SODIUM Form and strength CAPSULE;ORAL - 750MG Sponsor GE HEALTHCARE Submission history Latest submission status date: 1995-02-22 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.